Plain-English translation of NCT07402915 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new cancer medication called that is designed to fight ovarian, fallopian tube, and peritoneal cancers. The study also looks at how a common antifungal drug () affects how your body processes this new medication. Researchers want to understand whether these two drugs can be safely used together.
When patients take multiple medications at the same time, they can affect how each other works in the body. This study exists to make sure that if patients need both this medication and an antifungal drug, doctors will know it's safe and how to use them together.
You likely qualify if…
You likely don't qualify if…
You would receive intravenous infusions of the new medication every 3 weeks, with an antifungal pill taken by mouth during the first three cycles (about 9 weeks). After that, you would continue receiving the intravenous medication every 3 weeks on its own until your cancer stops responding, side effects become too severe, or your doctor determines you should stop. You would have regular visits to the clinic for treatment and to monitor your health and how well the medication is working.
AI-generated summary from trial data · Jul 9, 2026 · Not medical advice
Georgia
Ireland
Portugal